Clovis Oncology (CLVS) Misses Q1 EPS by 18c

Clovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($1.54), $0.18 worse than the analyst estimate of ($1.36). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $18.33 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c